Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KY-02327, a metabolically stabilized analog of KY-02061, serves as a potent inhibitor of the Dishevelled (Dvl)-CXXC5 interaction. This compound activates the Wnt/β-catenin pathway, thereby promoting osteoblast differentiation.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 53,000 |
5 mg | 在庫あり | ¥ 91,500 |
10 mg | 在庫あり | ¥ 136,000 |
25 mg | 在庫あり | ¥ 217,500 |
50 mg | 在庫あり | ¥ 294,000 |
100 mg | 在庫あり | ¥ 397,000 |
500 mg | 在庫あり | ¥ 796,500 |
説明 | KY-02327, a metabolically stabilized analog of KY-02061, serves as a potent inhibitor of the Dishevelled (Dvl)-CXXC5 interaction. This compound activates the Wnt/β-catenin pathway, thereby promoting osteoblast differentiation. |
In vitro | KY-02327 treatment (1-10 μM; 2 days) on MC3T3E1 cells, a murine pre-osteoblast cell line, enhances β-catenin protein level and Runx2, as well as nuclear β-catenin accumulation, in a dose-dependent manner [1]. Additionally, KY-02327 (1-10 μM) elevates the mRNA expression of osteoblast differentiation markers, collagen 1a (Col1a) and osteocalcin (OCN) [1]. |
In vivo | KY-02327 (20 mg/kg; p.o.; administered for 5 consecutive days each week for 4 weeks) effectively mitigates bone loss in an ovariectomized (OVX) mouse model, marking it as a promising candidate for osteoporosis treatment that stimulates bone growth[1]. In this study, 8-week-old female BL6 mice were used as the animal model for OVX-induced osteoporosis[1]. The dosage was set at 20 mg/kg with oral administration following the specified regimen. The result observed was an increase in newly formed bones, as indicated by calcein labeling, in the femur of the OVX mice treated with KY-02327, in contrast to the reduced bone formation in vehicle-treated OVX mice. |
分子量 | 373.45 |
分子式 | C20H27N3O4 |
CAS No. | 2093407-25-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (267.77 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
KY-02327 2093407-25-9 Others Wnt CXXC5 osteoblast differentiation inhibit KY 02327 anti-osteoporosis Dishevelled bone KY02327 Inhibitor anabolic inhibitor